🇪🇺 Anthim in European Union

Anthim (OBILTOXAXIMAB) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/005169
  • Local brand name: Nyxthracis (previously Obiltoxaximab SFL)
  • Status: withdrawn

Anthim in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Anthim approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Anthim in European Union?

Elusys Therapeutics Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.